Scotia Capital Inc. Cellectar Biosciences, Inc. Transaction History

Scotia Capital Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$3.5 - $6.9 $948 - $1,869	-271 Reduced 2.33%	11,360 $5,000
Q1 2022 May 09, 2022	BUY	$4.6 - $7.8 $1,246 - $2,113	271 Added 2.39%	11,631 $8,000
Q4 2021 Feb 11, 2022	BUY	$6.1 - $10.2 $896 - $1,499	147 Added 1.31%	11,360 $8,000
Q3 2021 Nov 12, 2021	BUY	$8.2 - $12.4 $91,946 - $139,041	11,213 New	11,213 $10,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Scotia Capital Inc. with notifications on news.